ArticleFrontiers in public health2025
Short- and long-term outcomes following COVID-19 or Influenza hospitalization in adults: results of the AUTCOV study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Large-scale registry-based studies on patients hospitalized with COVID-19 as compared to Influenza are scant, yet they are needed to re-evaluate the pandemic and the characteristics of patients at risk of severe outcomes. Methods: In this registry-based study from Austria, we examined short- and long-term outcomes after hospital admission due to COVID-19 or Influenza, also focusing on outcomes conditional on hospital survival. Data were provided on adults hospitalized with COVID-19 in the years 2020 and 2021 or with Influenza in 2016-2021, as well as on matched controls from the Austrian population. Analyses were performed separately for the four age groups (19-40, 41-64, 65-74, and ≥75 years). Results: Hospitalized COVID-19 and Influenza patients had a larger medication load as compared to the general population. Across all investigated age groups, polypharmacy was more frequent in the Influenza group. The risk for all-cause death in the entire follow-up period and death during hospital stay was higher in the COVID-19 group as compared to the Influenza group for all age groups ≥41 years. Furthermore, the duration of hospitalization was longer in patients with COVID-19. Notably, readmission rates were higher in Influenza patients, and mortality of hospital survivors was increased in younger Influenza patients aged 41-64 compared to COVID. Conclusion: In the first 2 years of the pandemic, COVID-19 had devastating effects on a non-immunized population, mainly in older patients and in patients with pre-existing serious comorbidities, but the health consequences of Influenza should not be underestimated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.